Lido Advisors LLC Sells 459,416 Shares of Edwards Lifesciences Co. (NYSE:EW)

Lido Advisors LLC cut its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 95.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,642 shares of the medical research company's stock after selling 459,416 shares during the period. Lido Advisors LLC's holdings in Edwards Lifesciences were worth $1,454,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Northern Trust Corp increased its holdings in shares of Edwards Lifesciences by 21.8% in the fourth quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after purchasing an additional 1,165,845 shares during the last quarter. Quarry LP raised its holdings in Edwards Lifesciences by 117.9% in the 4th quarter. Quarry LP now owns 6,997 shares of the medical research company's stock valued at $518,000 after acquiring an additional 3,786 shares during the period. Shorepoint Capital Partners LLC lifted its position in Edwards Lifesciences by 2.6% during the fourth quarter. Shorepoint Capital Partners LLC now owns 69,662 shares of the medical research company's stock worth $5,157,000 after acquiring an additional 1,737 shares during the last quarter. Prosperity Consulting Group LLC boosted its holdings in shares of Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after acquiring an additional 134 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $33,945,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 5,980 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the sale, the chief executive officer now owns 58,284 shares in the company, valued at approximately $4,366,054.44. The trade was a 9.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 77,833 shares of company stock valued at $5,611,023 over the last ninety days. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EW. Evercore ISI decreased their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Piper Sandler upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $73.00 to $80.00 in a research note on Thursday, April 24th. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Finally, Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and a consensus target price of $79.45.

Edwards Lifesciences Trading Up 0.1 %

NYSE:EW traded up $0.08 during mid-day trading on Wednesday, hitting $75.00. 615,558 shares of the company's stock were exchanged, compared to its average volume of 5,001,810. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a 50 day simple moving average of $71.30 and a 200-day simple moving average of $71.41. The firm has a market capitalization of $44.09 billion, a P/E ratio of 10.75, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.66 earnings per share. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.